AR and prostate cancer: These tumors often exhibit active FGF receptor and MAPK signaling to bypass the AR pathway for sustained prostate cancer growth, and initial preclinical experiments with selective inhibitors show in vitro and in vivo efficacy in double-negative prostate cancer models [32].